Email Updates

You are here


PrEP works. Investment in more options must continue, and faster, smarter rollout must be a top priority.

Clinical trials have shown that different types of pre-exposure prophylaxis (PrEP) using antiretroviral (ARVs) drugs dramatically reduce the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal. Meanwhile the landscape is changing as more options move through research, regulatory review or enter the market, intensifying the need to improve implementation.

TDF/FTC is approved for use as oral PrEP in dozens of countries, but PrEP still has not reached many of the people who need it most. Since TDF/FTC (brand name Truvada) was approved in 2012, F/TAF has been approved for men who have sex with men (MSM) and transgender women but not for cisgender women, and cabotegravir has been found to be safe and effective also among MSM and transgender populations. Find more information on cabotegravir on PrEPWatch.

For all these interventions and other ARVs still in the R&D pipeline, advocacy is crucial: There must be continued investment in the development of additional options, community engagement must be integrated from trial design to implementation, and improved programming must support those who need HIV prevention options the most.

Key Update

AVAC welcomes new, additional data that shows an injectable antiretroviral for HIV PrEP is safe and highly effective in reducing HIV risk cisgender men and transgender women who have sex with men.

July 7, 2020
What We're Reading

A promotional program designed to educate patients on HIV risk and prevention saw use of a preventive drug regimen among at-risk groups in Africa increase by more than 50 percent, according to a study published Wednesday by the journal Science Translational Medicine.

September 23, 2020

A small but significant proportion of gay and bisexual men with prescriptions for HIV pre-exposure prophylaxis (PrEP) have been sharing their medication with others, a new study finds.

September 14, 2020

The daily drug regimen known as PrEP is a nearly foolproof way to prevent HIV infection. But a new study suggests that many high-risk Americans may be giving the medication a pass because of cost.

September 10, 2020
US News & World Report
Subscribe to RSS - PrEP